Statements (23)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:CEO |
Anna Protopapas
|
gptkbp:collaboratesWith |
gptkb:Takeda_Pharmaceutical_Company
gptkb:Merck_KGaA |
gptkbp:country |
gptkb:United_States
|
gptkbp:focus |
oncology
antibody-drug conjugates |
gptkbp:foundedYear |
2001
|
gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts
|
https://www.w3.org/2000/01/rdf-schema#label |
Mersana Therapeutics
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:numberOfEmployees |
~100 (as of 2023)
|
gptkbp:platform |
Dolaflexin
Immunosynthen |
gptkbp:products |
UpRi (Upifitamab rilsodotin)
XMT-1660 XMT-2056 |
gptkbp:publiclyTraded |
true
|
gptkbp:stockExchange |
gptkb:NASDAQ
|
gptkbp:stockSymbol |
MRSN
|
gptkbp:website |
https://www.mersana.com/
|
gptkbp:bfsParent |
gptkb:David_Elmaleh
|
gptkbp:bfsLayer |
7
|